Author(s):
Mukilan. D, Sanvas. U, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M
Email(s):
hodpchemistry@velsuniv.ac.in
DOI:
10.5958/0974-360X.2020.00522.3 
Address:
Mukilan. D1, Sanvas. U1, Praveen. D2, Ranadheer Chowdary. P2, Vijey Aanandhi. M3*
1Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
2Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 6,
Year - 2020
ABSTRACT:
Over a long period of time the graft rejection post renal transplant has been a major concern across the globe. Several medications have been used for longer period of time as immune suppressant to prevent the graft rejection. Though these agents suppress the immune system it also brings about several toxic side effects as well as risks of rejection after transplantation. Recent updates in practice suggest the use of drugs such as Calcineurin Inhibitor, Anti-Proliferative drug and Steroids to a great extent. These three-drug-combination mainly inhibits the activation of B and T lymphocytes and guanosine nucleotide synthesis and thereby effectively suppresses the immune system and prevents the graft rejection. Hence triple suppression therapy is considered as the most effective one for preventing the graft rejection to the maximum and should be recommended worldwide.
Cite this article:
Mukilan. D, Sanvas. U, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M. A Comprehensive Review on Triple Suppression in patient with Post Renal Transplant. Research J. Pharm. and Tech 2020; 13(6): 2951-2953. doi: 10.5958/0974-360X.2020.00522.3
Cite(Electronic):
Mukilan. D, Sanvas. U, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M. A Comprehensive Review on Triple Suppression in patient with Post Renal Transplant. Research J. Pharm. and Tech 2020; 13(6): 2951-2953. doi: 10.5958/0974-360X.2020.00522.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-75
REFERENCES:
1. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am SocNephrol. 1998; 9(8):1511–20.
2. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64(6): 672–83.
3. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006; 26:1771–83.
4. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2:48–56.
5. Placebo-controlled study of mycophenolatemofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995; 345(8961): 1321–5.
6. A blinded randomized clinical trial of mycophenolatemofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61(7): 1029–37.
7. Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008; 8:144–9
8. Knechtle SJ, Pirsch JD, H Fechner J, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003; 3: 722–30.
9. Chegounchi M, Hanna MG, Neild GH. Progressive neurological disease induced by tacrolimus in a renal transplant recipient: Case presentation. BMC Nephrol 2006; 7:7.
10. Parvex P, Pinsk M, Bell LE, O’Gorman AM, Patenaude YG, Gupta IR. Reversible encephalopathy associated with tacrolimus in pediatric renal transplants. Pediatr Nephrol 2001;16(7): 537-42.
11. Grimbert P, Azema C, Pastural M, Dhamane D, Remy P, Salomon L, et al. Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient. Nephrol Dial Transplant 1999;14(10): 2489-91.
12. De SP, Petruccelli S, Precisi A, et al. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient – not all proliferation signal inhibitors are the same: a case report. Transplant Proc. 2007; 39: 3500–1.
13. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008; 22:125–130.
14. Muirhead N, House A, Hollomby DJ, Jevnikar AM. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc. 2003; 35: 2412–14
15. Moro JA, Almenar L, Martinez-Dolz L, et al. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc. 2008; 40:3034–6
16. Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients (ASCERTAIN) study (A2413). ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00170846?term=crad001a2413&rank=1.
17. Holdaas H, Bentdal O, Pfeffer P, et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant. 2008; 22:366–71.